Shanghai ZJ Bio-Tech Valuation

Is 688317 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688317 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688317 (CN¥18.73) is trading above our estimate of fair value (CN¥0.74)

Significantly Below Fair Value: 688317 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688317?

Key metric: As 688317 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688317. This is calculated by dividing 688317's market cap by their current revenue.
What is 688317's PS Ratio?
PS Ratio	17.2x
Sales	CN¥206.71m
Market Cap	CN¥3.56b

688317 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4x
Enterprise Value/EBITDA	-3.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 688317's PS Ratio compare to its peers?

The above table shows the PS ratio for 688317 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	10.2x
688075 Assure Tech (Hangzhou)	8.9x	n/a	CN¥5.3b
688399 Jiangsu Bioperfectus Technologies	11.3x	n/a	CN¥4.5b
300942 Shenzhen Bioeasy Biotechnology	13.8x	n/a	CN¥3.4b
688606 Hangzhou Alltest Biotech	6.7x	n/a	CN¥5.4b
688317 Shanghai ZJ Bio-Tech	17.2x	n/a	CN¥3.6b

Price-To-Sales vs Peers: 688317 is expensive based on its Price-To-Sales Ratio (17.2x) compared to the peer average (10.2x).

Price to Sales Ratio vs Industry

How does 688317's PS Ratio compare vs other companies in the CN Medical Equipment Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
300358 Truking Technology	0.8x	10.9%	US$632.78m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 688317 is expensive based on its Price-To-Sales Ratio (17.2x) compared to the CN Medical Equipment industry average (6.1x).

Price to Sales Ratio vs Fair Ratio

What is 688317's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688317 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	17.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 688317's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥7.1b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥16.65

-4.6%

-27.1%

Truking Technology

CN¥4.6b

Engages in medical equipment business in China and internationally.

300358

CN¥7.76

-3.8%

-35.3%

iRay Technology

CN¥16.4b

Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.

688301

CN¥114.87

-10.7%

-32.1%